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Edited by Ulrike KutayAbstract Various drugs such as phenobarbital (PB) trigger
translocation of constitutive active/adrostane receptor (CAR)
from the cytoplasm into the nucleus of mouse liver cells without
directly binding to the receptor. We have now characterized the
guanine nucleotide exchange factor epithelial cell-transforming
gene 2 (ECT2) as a PB-inducible factor as well as a cellular sig-
nal that represses PB-triggered nuclear translocation of CAR.
When CFP-tagged ECT2 was co-expressed with YFP-tagged
CAR in the liver of Car/ mice, ECT2 repressed CAR nuclear
translocation. Coexpression of various deletion mutants delin-
eated this repressive activity to the tandem Dbl homology/pleck-
strin homology domains of ECT2 and to their cytosolic
expression. CAR directly bound to the PH domain. Thus,
ECT2 may comprise a part of the PB response signal regulating
the intracellular traﬃcking of CAR.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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As the major organ for drug detoxiﬁcation and excretion,
the liver is endowed with the capability of inducing drug
metabolizing enzymes and transporters in response to drug
exposures. Upon activation by drugs such as phenobarbital
(PB) and phenytoin, constitutive active/adrostane receptorAbbreviations: CAR, constitutive active/adrostane receptor; PXR,
pregnane X receptor; RXR, retinoid X receptor; ECT2, epithelial
cell-transforming gene 2; PH, pleckstrin homology; DH, Dbl homol-
ogy; TCPOBOP, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene; PB, phe-
nobarbital
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the receptor forms a heterodimer with retinoid X receptor
(RXR) to up-regulate transcription of the genes that encode
drug metabolizing enzymes such as cytochromes P450 and
the drug transporters [1–5]. The function of CAR has now
been extended to the regulation of drug-induced repression
of hepatic gluconeogenesis, by cross talking with the insulin re-
sponse FoxO1 transcription factor to repress the genes such as
glucose-6-phosphatase and phosphoenoylpyruvate carboxyki-
nase 1 [6,7]. In liver during regeneration, CAR up-regulates
the expression of the deiodinase 1 gene increasing thyroid hor-
mone activity [8]. Also CAR is characterized as the essential
factor for PB promotion of development of hepatocellular car-
cinoma [9]. Thus, deciphering the molecular mechanism of
CAR activation by drugs is now critical for us to understand
the receptor-mediated drug eﬀects on liver functions and dis-
eases.
Drug activation of CAR begins with the nuclear transloca-
tion from the cytoplasm of liver cells into the nucleus [10]. Un-
like the nuclear steroid hormone receptors, for which their
nuclear translocation is dictated by direct ligand binding,
CAR is unique in which its nuclear translocation occurs with-
out direct binding of its activators [11,12]. Although a cellular
signal pathway may be present to retain CAR in the cyto-
plasm, no such a signal has yet been identiﬁed. epithelial
cell-transforming gene 2 (ECT2) was originally cloned from
epithelial cells and was characterized as a guanine nucleotide
exchange factor bearing oncogenic activity [12–19]. We have
linked ECT2 with CAR based on observations obtained in
two independent analyses: (1) cDNA microarray analysis of
wildtype and Car/ mice after hepatectomy and PB treat-
ment; and (2) looking for genes up-regulated during PB-pro-
moted development of liver tumors [9]. Given these
serendipitous ﬁndings, we pursued more detailed studies of
ECT2, examining whether or not it regulates drug-induced nu-
clear translocation of CAR. By tail vein injection of expression
plasmid DNAs, ﬂuorescent protein tagged-ECT2 and its dele-
tion mutants were directly co-expressed with CAR in mouse
livers of Car/ mice. ECT2 and CAR were also co-expressed
in HepG2 cells for co-immunoprecipitation assays to deﬁne the
molecular basis for their interaction. Thus, here we present
experimental evidence that ECT2 directly interacts with
CAR in the cytoplasm of liver cells to repress PB-induced
CAR nuclear translocation.European Biochemical Societies.
Fig. 1. PB induction of ECT2 in the mouse liver. (A) PB (closed bar,
100 mg/kg body weight) or vehicle (open bar, saline) was intraperito-
neally injected into Car/ and Car+/+ mice. After 24 h, total liver
RNA was isolated and subjected to real-time PCR as described in
Section 2. Each sample was performed in triplicate. (B) Liver cytosols
were prepared from Car+/+ mice at 6 and 24 h after intraperitoneal
injection of PB (100 mg/kg) and were subjected to immunoblotting
analysis using anti-ECT2 antibody.
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2.1. Materials
1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP), anti-Flag
HRP and anti-Flag M2-agarose were obtained from Sigma (St. Louis,
MO); goat polyclonal GFP (HRP) antibody from Abcam Inc. (Cam-
bridge, MA); Rabbit anti-hECT2 from Santa Cruz Biotechnology;
and Complete Mini protease inhibitor cocktail tablets from Roche
Diagnostics GmbH (Indianapolis, IN).
2.2. Plasmids
pEYFP-c1-mCAR and pEYFP-c1-mPXR were previously con-
structed [20,21]. Full-length cDNA of ECT2 was PCR-ampliﬁed from
RNAs prepared from HepG2 cells using appropriate 5 0-primer having
an in-frame EcoRI site at the 5 0-end and 3 0 primer bearing the KpnI site
at the 3 0-end. The ampliﬁed cDNA was digested by these two enzymes
and cloned into pECFP-c1 (BD Biosciences) to produce
pECFP-c1-ECT2. Using pECFP-c1-ECT2 as a template and a Quik-
Change Site-Directed Mutagenesis kit (Stratagene, Cedar Creek, TX),
the expression plasmids for various ECT2 fragments were constructed:
pECFP-c1-NS (amino acid residues 1–150), pECFP-c1-Dbl homology
(DH)/pleckstrin homology (PH) (150–250), pECFP-c1-DH/PH/C
(150–300), pECFP-c1-DH (150–200) and pECFP-c1-PH (200–250).
To add a nuclear localization signal (NLS) sequence to the DHPH frag-
ment, its cDNAwas PCR-ampliﬁed using the appropriate 5 0 primer and
the 3 0 primer containing the BamHI site at the 3 0-end and cloned into
pECFP-Nuc expression vectors carrying simian virus 40 large T antigen
(BD Biosciences), to construct pECFP-Nuc-DH/PH. The BamHI and
EcoRI fragments of NS, DH, PHC and mCAR were inserted at the
BamHI and EcoRI sites of pACT or pBIND vector (Promega Co.,
Madison, WI). All plasmids were veriﬁed by nucleotide sequencing.
2.3. Immunoprecipitation
Anti-Flag M2-agarose (40 ll) was added to cytosol (1–2 mg of pro-
tein) prepared from HepG2 cells and incubated at 4 C for 16 h. The
remaining procedure was carried out as described previously [21].
2.4. Western blot
Western blot was carried out as described previously [21]. Mem-
branes were incubated for 1 h at 25 C with HRP-conjugated goat
anti-GFP polyclonal antibody or overnight with rabbit anti-hECT2
primary antibody followed by 1 h incubation with HRP-conjugated
donkey anti-rabbit IgG secondary antibody.
2.5. Animal experiments
Adult male Car+/+ and Car/ mice were used for all experiments.
Cytosolic fractions and nuclear extracts were prepared mouse livers
according to published methods [22,23]. Direct expression of ECT2
and/or CAR and analysis of their expression plasmids were performed
as described previously [20].
2.6. Mammalian two-hybrid assays
HepG2 cells were seeded into 24-well plates (1 · 105 cells/well) and
were co-transfected with pG5 (0.1 lg/well), pBIND-mCAR (0.2 lg/
well) and pACT-ECT2 (0.2 lg/well). Total amount of plasmids trans-
fected was adjusted by adding empty vector. Twenty-four hours after
transfection, the cells were washed with PBS, supplemented with fresh
serum-free medium and treated with 250 nM TCPOBOP or vehicle for
24 h prior to luciferase activity analysis. Luciferase activities were mea-
sured in cell lysates using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI) as described previously [23].
2.7. Real-time PCR
Liver was homogenized in TRIzol reagent (Invitrogen, Carlsbad,
CA) to prepare total RNA according to the manufacturer’s instruc-
tions. Two micrograms of RNA was used as a template for cDNA
synthesis using the SuperScript ﬁrst strand synthesis system (Invitro-
gen, Carlsbad, CA). One-twentieth of the cDNA was used for real-
time PCR with an ABI Prism 7700 sequence detector using TaqMan
Universal PCR reaction mix, and primers for mouse ECT2
(Mm00432964, Applied Biosystems, Foster City, CA) or CYP2B10
[26] genes were used for ampliﬁcation. Ampliﬁcation of the glyceral-
dehyde-3-phosphate gene was used as a normalization control.3. Results and discussion
3.1. CAR-mediated induction of ECT2
We ﬁrst examined induction of ECT2 by PB in the livers of
normal mice. Treatment with PB for 24 h resulted in a 3-fold
induction of ECT2 mRNA in the wildtype but not in the
Car/ livers (Fig. 1A). These results indicate that ECT2 is a
PB-inducible and CAR-regulated factor. Car+/+ mice were
treated by PB for 6 and 24 h, from which cytosolic fractions
were prepared to examine the levels of ECT2 protein. Western
blot analysis revealed that 6 h PB treatment increased ECT2
protein levels in both cytosolic and nuclear fractions
(Fig. 1B). The cytosolic levels of ECT2 remained elevated after
24 h treatment, while no detectable ECT2 was observed in the
nuclear factions.
3.2. Inhibition of CAR nuclear translocation by ECT2
ECT2 is known to regulate intracellular protein traﬃcking
[19]. Therefore, we examined whether ECT2 can regulate nu-
clear translocation of CAR in mouse liver. For this, Car/
mice were tail vein-injected with the appropriate plasmids to
give liver expression of YFP-CAR with or without co-expres-
sion of CFP-ECT2. Confocal analysis of liver sections from
these plasmid-injected mice revealed that YFP-CAR was local-
ized in the cytoplasm, and upon PB treatment CAR translo-
cated to the nucleus (Fig. 3A). However, when CFP–ECT2
was co-expressed with YFP–CAR, the CFP–CAR remained
localized in the cytoplasm even after PB treatment (Fig. 3B).
Analysis of one hundred PB-treated hepatocytes revealed that
the number of the hepatocytes localizing CAR in the nucleus
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This inhibition of CAR nuclear translocation by ECT2 ap-
peared to be speciﬁc to CAR, since CFP–ECT2 was found
not to aﬀect intracellular localization of pregnane X receptor
(PXR) in the liver in the presence and absence of the PXR ago-
nist pregnenolone-16a carbonitrile (PCN) (Fig. 3D,E). It re-
mains an interesting question whether the speciﬁcity isFig. 2. Schematic representations of domain structure of ECT2 and of the de
published by Solski et al. [24].
Fig. 3. ECT2 inhibition of CAR nuclear translocation in the liver. (A) Car/
and were treated with saline (PB) or PB (+PB) as described in Section 2. L
CAR expression (yellow) and Hoechest S33258 was used to stain nuclei (red).
YFP-CAR and CFP-ECT2 and were treated with saline (PB) or PB (+PB).
CAR expression (yellow) and ECT2 expression (blue). Hoechest S33258 was u
CAR and ECT2 were counted, and CAR subcellular localization was categori
(D) and (E) YFP-PXR localization and eﬀects of PCN treatment were assesoriginated from the diﬀerences in the molecules of the two
receptors and/or in the signals generated by PB and PCN.
3.3. Delineation of the CAR binding site of ECT2
Given the possibility that ECT2 might bind to CAR in
repressing the nuclear translocation, co-immunoprecipitation
(co-IP) and mammalian two-hybrid analyses were performedletion mutants. This domain structure is depicted based on information
mice were trail vein-injected with the expression plasmid of YFP-CAR
iver sections were prepared and examined by confocal microscopy for
(B) Car/ mice were trail vein-injected with the expression plasmids of
Liver sections were prepared and examined by confocal microscopy for
sed to stain nuclei (red). (C) One hundred hepatocytes expressing both
zed into two groups: cytoplasmic (open bars) and nuclear (closed bars).
sed, using the same analysis as in (B) and (C).
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tion. Based on the subdomain structure of ECT2 (Fig. 2),
expression plasmids encoding single or multiple subdomains
were constructed. In co-I P experiments, pECFP-c1-NS, pEC-
FP-c1-NS/DH, pECFP-c1-DH/PH, pECFP-c1-DH, or pEC-
FP-c1-PH was co-transfected with Flag-mCAR in HepG2
cells and cytosols were prepared. Using anti-Flag M2-agarose
Flag-CAR was puriﬁed, and associated ECT2 protein was de-
tected by an anti-CFP antibody. The results showed that the
PH domain alone is suﬃcient for ECT2 to interact with
CAR (Fig. 4A). In mammalian two-hybrid assay analysis,
pBIND-mCAR was co-transfected pACR-NS, pACR-DH or
pACR-PH/C. The 2-fold increase in the luciferase activity with
CAR and ECT2-PH/C co-transfection conﬁrmed the interac-
tion of ECT2’s PH domain with CAR (Fig. 4B).
3.4. Requirement of DH domain in repressing CAR
translocation
In order to investigate the role of ECT2 in repressing PB-
dependent CAR nuclear translocation, a single CFP-tagged
ECT2 deletion construct (NS, DH/PH, DH/PH/C, DH, orFig. 4. Delineation of the CAR binding site to PH domain. (A)
Various CFP-tagged ECT2 fragments were co-expressed with Flag-
tagged mCAR in HepG2 cells as described in Section 2. Using HepG2
cell cytosol (1 mg protein), co-immunoprecipitation was carried out by
anti-Flag antibody-conjugated agarose and was subjected to immu-
noblot analysis by anti-Flag HRP antibody. Input samples were 5% of
the cytosol protein used for co-immunoprecipitations. (B) Mammalian
two hybrid assays to show the interaction of CAR with PH domain.
All experiments were performed as described in Section 2. The
luciferase activity levels are indicated as the means ± S.D. of triplicate
determinations, and shown is a representative result obtained in three
independent experiments.PH) was co-expressed with YFP–CAR in Car/ mouse liver,
followed by PB treatment. The percentage of cells with nucle-
ar-localized YFP–CAR was then determined, normalized to
the percentage of cells with nuclear-localized YFP–CAR in
mice not co-expressing CFP-tagged ECT2. Of all the CFP–
ECT2 deletion constructs, expression of the tandem DH/PH
construct caused the greatest reduction (by approximately
90%) in PB-elicited YFP–CAR nuclear translocation (Fig. 5).
In contrast to the strong inhibition by the DH/PH, expression
of either the DH or PH domain alone did not inhibit the YFP–
CAR nuclear translocation. These data suggest that the DH
and PH domains must both be present for ECT2 to inhibit
the nuclear translocation of CAR. Interestingly, the presence
of the carboxyl (C) domain attenuated the inhibitory eﬀect
of the DH/PH on CAR translocation as revealed by only a
50% inhibition of translocation by full-length ECT2 and the
ECT2-DH/PH/C.3.5. Cytoplasmic localization of the DH/PH
When its expression plasmid was injected via mouse tail
vein, CFP-DH/PH was exclusively expressed in the cytoplasm
of mouse hepatocytes and this cytoplasmic localization was
unaﬀected after the mouse being treated with PB (Fig. 6).
To answer the question whether the cytoplasmic localization
was required for DH/PH to inhibit the PB-induced nuclear
localization of CAR, the expression plasmid pECFP-Nuc-
DH/PH was constructed to force the DH/PH localizing in
the nucleus by adding a nuclear translocation signal (NLS)
(Fig. 6). CFP-Nuc-DH/PH by itself did not carry CAR into
the nucleus, since co-expressed YFP-CAR was retained in
the cytoplasm. Moreover, unlike co-expression of CFP-DH/
PH that eﬀectively inhibited PB-induced nuclear translocation
of YFP–CAR, the co-expression CFP-Nuc-DH/PH did not
inhibit this translocation. Cell counting revealed that 70%Fig. 5. Delineation of the inhibitory activity to the DH/PH. YFP-
tagged CAR and a CFP-tagged ECT2 were co-expressed in the Car/
livers by tail-vein injecting their expression plasmids. Livers were
removed from these mice after PB treatment and sections prepared and
were examined by confocal microscopy. The number of hepatocytes
having predominately nuclear YFP-CAR localization (out of 100 total
hepatocytes) was divided by the number of cells expressing CAR in the
nucleus (out of 100 total hepatocytes), giving a percentage. The
percentage of cells with nuclear CAR when ECT2 was not co-
expressed was set as 100%.
Fig. 6. Cytoplasmic localization-dependent inhibition of CAR translocation by ECT2. YFP-tagged mCAR and either CFP-tagged DH/PH or CFP-
tagged Nuc-DH/PH were co-expressed in the liver of Car/ mice by tail-vein injection of their expression plasmids as described in Section 2. Mice
were treated with saline (PB) or PB (+PB), and liver sections were then prepared and examined by confocal microscopy for mCAR expression
(yellow) and ECT2 expression (blue). Hoechest S33258 was used to stain nucleus (red).
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cleus. These results equivocally show that DH/PH must be
present in the cytoplasm to inhibit PB-induced CAR nuclear
translocation.
3.6. No repression by ECT2 of CAR-mediated transcription
Unlike CAR in non-induced mouse liver, CAR spontane-
ously accumulates in the nucleus of HepG2 cells [10,11]. There-
fore, we used HepG2 cells to examine whether ECT2 directly
represses CAR-mediated transcriptional activation. For this,
the (NR1)5-tk-luciferase reporter and pEYFP-c1-mCAR plas-
mids were co-transfected with pECFP-c1-ECT2, pECFP-c1-
DH/PH, or pECFP-c1-Nuc-DH/PH. The CAR agonist TCPO-
BOP activated the NR1 reporter activity, and neither full-
length ECT2 nor any of the deletion mutants repressed the
CAR-mediated activation of (NR1)5-tk-luciferase reporter
(Fig. 7). These results indicate that ECT2 does not inhibit
the activation function of CAR at the level of transcription
in the nucleus.4. Conclusion
Based on our ﬁndings, we propose that ECT2 may consti-
tute a part of the cellular mechanism repressing PB activation
of CAR by inhibiting the nuclear translocation of the receptor
in the mouse hepatocytes. In addition to the cytoplasm and
the nucleus, CAR also localizes to other compartments, most
notably the cell membrane [25]. Furthermore, the nuclear le-
vel of CAR peaks in the liver 3–6 h after PB injection [10],
and we have found that a second treatment PB injection at
24 h after the ﬁrst treatment no longer accumulates CAR in
the nucleus (data not shown). These observations imply the
possibility that hepatocytes are endowed with a negative feed-
back mechanism repressing PB-induced nuclear translocation
of CAR and regulating CAR-mediated transcription of hepa-
tic genes. Growth factors such as hepatocyte growth factor re-
press the CAR nuclear translocation in mouse primary
hepatocytes [26], which may, in part, be due to the fact that
they induce ECT2 [18]. Thus, PB may trigger the negative
Fig. 7. No repression by ECT2 of CAR-mediated transactivation.
HepG2 cells were transfected with pECFP-c1-ECT, pECFP-c1-DH/
PH, pECFP-c1-Nuc-DH/PH or empty pECFP-c1 with both pEYFP-
c1-CAR and (NR1)5-tk-luciferase reporter plasmids. Twenty-four
hours after transfection, the cells were treated with 250 nM TCPOBOP
or DMSO for an additional 24 h and luciferase activities were
determined as described in Section 2. Fireﬂy luciferase activity was
normalized against Renilla reniformis luciferase activity, and the
means ± standard deviation was calculated based on triplicate deter-
minations. Shown is a representative result in three independent
experiments.
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